Clinical Trial

A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer

Study acronym: GC-Ib/II
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
In this study, the combination of Adebrelimab (PD-L1 monoclonal antibody) on the basis of standard treatment (two-drug chemotherapy regimen of fluorouracil and platinum drugs) may enhance the immune response in order to enhance the killing effect on tumor cells and bring survival benefits to patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.
Trial Details
NCT Number NCT06776770
Lead Sponsor Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Conditions Gastric Cancer
Enrollment 52 participants
Start Date 2024-08-03
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-15